Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Cash from Operations (2020 - 2025)

Cytek Biosciences' Cash from Operations history spans 6 years, with the latest figure at 771000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 138.61% year-over-year to 771000.0; the TTM value through Dec 2025 reached 4686000.0, down 118.46%, while the annual FY2025 figure was 4686000.0, 118.46% down from the prior year.
  • Cash from Operations reached 771000.0 in Q4 2025 per CTKB's latest filing, up from 3898000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 13221000.0 in Q3 2024 to a low of 9440000.0 in Q2 2022.
  • Average Cash from Operations over 5 years is 918650.0, with a median of 634500.0 recorded in 2021.
  • Peak YoY movement for Cash from Operations: plummeted 746.34% in 2022, then skyrocketed 411.89% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 5448000.0 in 2021, then grew by 13.67% to 6193000.0 in 2022, then surged by 53.59% to 9512000.0 in 2023, then plummeted by 79.01% to 1997000.0 in 2024, then tumbled by 138.61% to 771000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Cash from Operations are 771000.0 (Q4 2025), 3898000.0 (Q3 2025), and 108000.0 (Q2 2025).